89bio, Inc (ETNB)

Etorro trading 970x250
89bio, Inc (ETNB) Logo

About 89bio, Inc

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is BIO89-100, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop BIO89-100 for the treatment of severe hypertriglyceridemia. 89bio, Inc. was founded in 2018 and is based in San Francisco, California. Address: 142 Sansome Street, San Francisco, CA, United States, 94104

89bio, Inc News and around…

Latest news about 89bio, Inc (ETNB) common stock and company :

Analysts Expect 15% Gains Ahead For The Holdings of VTWV
27 Oct, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Russell 2000 Value ETF (VTWV), we found that the implied analyst target price for the ETF based upon its underlying holdings is $168.49 per unit.

89bio to Present New Sub-Analysis from Phase 1b/2a NASH Study of BIO89-100 at AASLD’s The Liver Meeting 2021
25 Oct, 2021 Yahoo! Finance

Data from a new sub-analysis of the Phase 1b/2a study in NASH shows correlation between increased liver fat and spleen volume in patients with non-cirrhotic NASHSAN FRANCISCO, Oct. 25, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that a sub-analysis of its Phase 1b/2a proof-of-concept study of BIO89-1

Is 89bio, Inc. (ETNB) A Good Stock To Buy?
04 Oct, 2021 Yahoo! Finance

Is 89bio, Inc. (NASDAQ:ETNB) a good place to invest some of your money right now? We can gain invaluable insight to help us answer that question by studying the investment trends of top investors, who employ world-class Ivy League graduates, who are given immense resources and industry contacts to put their financial expertise to work. […]

How The Parts Add Up: VTHR Targets $227
22 Sep, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Russell 3000 ETF (VTHR), we found that the implied analyst target price for the ETF based upon its underlying holdings is $226.75 per unit.

89bio to Participate in the Cantor Global Healthcare Conference
21 Sep, 2021 FinancialContent
89bio to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
08 Sep, 2021 FinancialContent
89bio Reports Second Quarter 2021 Financial Results and Provides Corporate Update
12 Aug, 2021 FinancialContent
89bio to Participate in Upcoming Investor Conferences
03 Aug, 2021 FinancialContent
89bio Completed Target Enrollment in Histology Cohort to Evaluate BIO89-100 for the Treatment of NASH
02 Aug, 2021 FinancialContent

- Study designed to build upon positive Phase 1b/2a data and provide an early opportunity to demonstrate BIO89-100’s potential benefits on histology endpoints -

The Daily Biotech Pulse: Erytech Jumps On Fast Track Designation, GlaxoSmithKline FDA Nod, Alnylam's Clinical Collaboration, 4 IPOs
30 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Stocks That Hit 52-Week Lows On Thursday
29 Jul, 2021 FinancialContent

Before 10 a.m. ET on Thursday, 15 companies set new 52-week lows. Noteworthy Mentions: Citrix Systems ...

The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs
29 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal
28 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Sum Up The Pieces: IWN Could Be Worth $187
19 Jul, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Russell 2000 Value ETF (IWN), we found that the implied analyst target price for the ETF based upon its underlying holdings is $187.45 per unit.

The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study
16 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs
15 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

12 Health Care Stocks Moving In Monday's After-Market Session
12 Jul, 2021 FinancialContent

Gainers SCWorx (NASDAQ:WORX) shares rose 27.06% to $3.38 during Monday's after-market session. Today's trading volume for this ...

64 Biggest Movers From Friday
12 Jul, 2021 FinancialContent

Gainers Sentage Holdings Inc. (NASDAQ: SNTG) shares surged 597.8% to settle at $34.89 on Friday as the company priced its IPO at ...

12 Health Care Stocks Moving In Friday's Intraday Session
09 Jul, 2021 FinancialContent

Gainers Galectin Therapeutics (NASDAQ:GALT) shares moved upwards by 35.0% to $3.73 during Friday's regular session. ...

40 Stocks Moving In Friday's Mid-Day Session
09 Jul, 2021 FinancialContent

Gainers Stamps.com Inc. (NASDAQ: STMP) jumped 63.7% to $323.63. Software investment firm Thoma Bravo inked an agreement to acquire ...

The Daily Biotech Pulse: Lilly, Morphic's Positive Data At ECCO, Humanigen's COVID Treatment Gets Expedited Review In UK, TransCode IPO
09 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The CEO & Director of 89bio, Inc. (NASDAQ:ETNB), Rohan Palekar, Just Bought 23% More Shares
09 Jul, 2021 Yahoo! Finance

Investors who take an interest in 89bio, Inc. ( NASDAQ:ETNB ) should definitely note that the CEO & Director, Rohan...

The Daily Biotech Pulse: Priority Review For Amgen's Asthma Treatment, Evaxion Reports Positive Skin Cancer Readout, Quidel Recalls Lyra COVID-19 Test
08 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Stocks That Hit 52-Week Lows On Wednesday
07 Jul, 2021 FinancialContent

Before 10 a.m. ET on Wednesday, 49 companies set new 52-week lows. Noteworthy Highlights: The largest company in ...

The Daily Biotech Pulse: Opiant Spikes On Data, OncoSec Rallies On Merck Collaboration, XBiotech Special Dividend
07 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Stocks That Hit 52-Week Lows On Tuesday
06 Jul, 2021 FinancialContent

Tuesday morning, 51 companies reached new 52-week lows. Noteworthy Highlights: China Life Insurance Co ...

Peek Under The Hood: VTWG Has 21% Upside
17 Jun, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Russell 2000 Growth ETF (VTWG), we found that the implied analyst target price for the ETF based upon its underlying holdings is $268.58 per unit.

89bio Initiates Phase 2b ENLIVEN Trial of BIO89-100 for the Treatment of NASH
10 Jun, 2021 FinancialContent
Notable Insider Buys Of The Last Week: Bumble, Coty, Peloton Interactive, And More
29 May, 2021 FinancialContent

Some return buyers were among the insiders acquiring shares this last week. A beauty products company and an online dating outfit were among the firms that saw notable insider buying.

Notable Insider Buys Of The Last Week: Bumble, Coty, Peloton Interactive, More
29 May, 2021 FinancialContent

Insider buying can be an encouraging signal for potential investors, especially when markets are uncertain or near all-time ...

89bio, Inc (ETNB) is a NASDAQ Common Stock listed in , ,

970x250